Posted by medlib on June 24, 2002, at 13:05:28
In reply to What is GlaxoSK GW320659 nor/dop reup inhib ADD?, posted by 3 Beer Effect on June 23, 2002, at 17:42:53
Hi again 3B--
According to the GSK pipeline dated 5/17/02, GW320659 is still in Phase II, thus no name and no FDA activity yet. It's described as a beta 3 agonist; prelim rx indications for obesity, Type 2 diabetes, and/or ADHD.
Sorry--no kinder, gentler Wellbutrin on the immediate horizon that I know of---medlib
poster:medlib
thread:110565
URL: http://www.dr-bob.org/babble/20020617/msgs/110626.html